- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03034395
Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma
April 29, 2021 updated by: University of Kansas Medical Center
Pilot Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma
This is a randomized non-blinded pilot study for patients with melanoma staging cT2N0M0 who are candidates for surgical resection.
The primary objective is to determine the feasibility of randomizing participants with cT2N0M0 malignant melanoma to surgical treatment with 1cm versus 2cm margins.
Study will try to determine overall survival for cT2N0M0 malignant melanoma after surgical treatment with 1cm versus 2cm margins.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
After randomization, participants will undergo surgery with wide local excision with either 1cm or 2cm margins.
The margin will be based upon the previous biopsy site or area of pigmentation.
The skin and subcutaneous tissue (down to fascia) will be resected.
Closure considerations may require removal of additional tissue for non-oncologic purposes.
As per standard of care, sentinel lymph node biopsy will be performed using a dual tracer technique (technetium radiolabeled sulfur colloid and isosulfan blue) with or without lymphoscintigraphy.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Biopsy proven T2 malignant melanoma.
- Eastern Cooperative Oncology Group (ECOG) score of 0-2.
Exclusion Criteria:
- Visible additional disease that suggests a greater than T2 malignant melanoma
- Unable to tolerate general anesthesia
- Evidence of distant metastatic disease
- Melanoma located on face or digits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Wide Local Excision 1cm
|
Surgery
|
OTHER: Wide Local Excision 2cm
|
Surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who agree to blinded randomization to a surgical margin trial for the treatment of early stage melanoma.
Time Frame: 2 years
|
Number of patients who agree to participate
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence (disease free survival)
Time Frame: Every 4 months post-surgery for 2 years and then every 4-6 months for an additional 3 years
|
Subjects will be evaluated at 4 month intervals for 2 years and then at 4-6 month intervals for an additional 3 years to evaluate for evidence of disease recurrence.
|
Every 4 months post-surgery for 2 years and then every 4-6 months for an additional 3 years
|
Quality of life following surgery
Time Frame: One month post-surgery
|
Measured by FACT-Melanoma Surgery Subscale
|
One month post-surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Joshua Mammen, MD, University of Kansas Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 30, 2017
Primary Completion (ACTUAL)
May 3, 2019
Study Completion (ACTUAL)
November 4, 2020
Study Registration Dates
First Submitted
January 23, 2017
First Submitted That Met QC Criteria
January 26, 2017
First Posted (ESTIMATE)
January 27, 2017
Study Record Updates
Last Update Posted (ACTUAL)
May 3, 2021
Last Update Submitted That Met QC Criteria
April 29, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT-2016-JM-MEL-T2Margins
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsBelgium, Spain, Germany, Netherlands, Finland
-
Eli Lilly and CompanyCompletedMetastatic Malignant MelanomaUnited States
Clinical Trials on Wide Local Excision
-
Melanoma and Skin Cancer Trials LimitedNorfolk and Norwich University Hospitals NHS Foundation Trust; Peter MacCallum...Active, not recruitingCutaneous Melanoma by AJCC V7 StageUnited Kingdom, United States, Sweden, Australia, Canada
-
Melanoma and Skin Cancer Trials LimitedNorfolk and Norwich University Hospitals NHS Foundation Trust; Canadian Cancer... and other collaboratorsRecruitingCutaneous Melanoma, Stage IIUnited States, Canada, United Kingdom, Australia, Italy, Sweden, Netherlands, New Zealand
-
Wake Forest University Health SciencesAtrium Health Levine Cancer InstituteRecruitingVulvar Neoplasm | Dysplasia VulvarUnited States
-
Mayo ClinicCompletedDermatofibrosarcoma ProtuberansUnited States
-
Loma Linda UniversityCompletedSoft Tissue SarcomaUnited States
-
University of BalamandCompletedGastric HemorrhageLebanon
-
Ain Shams UniversityCompleted
-
AmgenRecruitingSmall Cell Lung Cancer | Limited Stage Small Cell Lung CancerTaiwan, Japan, Turkey, United States, Korea, Republic of
-
London North West Healthcare NHS TrustUnknownPilonidal Disease | Pilonidal Abscess | Pilonidal Sinus With Abscess | Pilonidal Sinus Infected
-
United States Naval Medical Center, PortsmouthUnknown